IP Verse

Pharmaceutical Combinations - EP3463345

The patent EP3463345 was granted to Array Biopharma on Nov 2, 2022. The application was originally filed on Jun 2, 2017 under application number EP17807555A. The patent is currently recorded with a legal status of "Revoked".

EP3463345

ARRAY BIOPHARMA
Application Number
EP17807555A
Filing Date
Jun 2, 2017
Status
Revoked
Mar 22, 2024
Grant Date
Nov 2, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

KRAUS & LEDERER PARTGMBBAug 1, 2023ADMISSIBLE
TER MEER STEINMEISTER & PARTNER PATENTANWALTE MBBAug 1, 2023ADMISSIBLE

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS6217866
DESCRIPTIONUS8501758
DESCRIPTIONWO03077914
DESCRIPTIONWO2011025927
DESCRIPTIONWO2013078264
DESCRIPTIONWO2014063024
DESCRIPTIONWO9640210
INTERNATIONAL-SEARCH-REPORTUS2014222443
INTERNATIONAL-SEARCH-REPORTUS2014275136
INTERNATIONAL-SEARCH-REPORTUS2015164897
INTERNATIONAL-SEARCH-REPORTUS2015265616
INTERNATIONAL-SEARCH-REPORTUS2015273057
OPPOSITIONWO2011025927
OPPOSITIONWO2014063024
OPPOSITIONWO2017210538
SEARCHWO2012170715
SEARCHWO2015087279

Non-Patent Literature (NPL) Citations (21) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- E. VAN CUTSEM ET AL., "O-027 BEACON CRC study safety lead-in: Assessment of the BRAF inhibitor encorafenib 1 MEK inhibitor binimetinib 1 anti-epidermal growth factor receptor antibody cetuximab for BRAFV600E metastatic colorectal cancer", ANNALS OF ONCOLOGY., NL, (20180601), vol. 29, doi:10.1093/annonc/mdy149, ISSN 0923-7534, XP055754374
OPPOSITION- Anonymous, "Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)", (20130726), pages 1 - 14, Clinical trials, (20191211), XP055651982-
OPPOSITION- Anonymous, "Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. lrinotecan/Cetuximab or Infusional 5-Fluorouracil (5- FU)/Folinic Acid (FA)/lrinotecan (FOLFIRl)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC) NCT02928224", ClinicalTrials, (20170501), pages 1 - 13, ClinicalTrials, (20231020), XP093093474-
OPPOSITION- Anonymous, "US prescribing information for Erbitux (cetuximab)", US prescribing information for Erbitux, (20150401), pages 1 - 34, US prescribing information for Erbitux, (20231020), XP093093523-
OPPOSITION- Johanna C Bendell, Atreya Chloe Evelyn, André Thierry, Tabernero Josep, Gordon Michael S, Bernards Rene, Cutsem Eric Van, Tejpar Sabine, Sidhu Roger, Go William Y, Allred Alicia, Motwani Monica, Suttle Benjamin B, Wu Yuehui, Hoos Axel, Orford Keith W, Corcoran Ryan Bruce, Schellens Jan Hm, "Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).", Journal of Clinical Oncology American Society of Clinical Oncology, (20140320), vol. 32, no. 15_Suppl, page 3515, XP055183040-
OPPOSITION- LEE MICHAEL S ET AL, "Novel Therapies in Development for Metastatic Colorectal Cancer.", GASTROINTESTINAL CANCER RESEARCH, International Society of Gastrointestinal Oncology, US, US , (20140901), vol. 7, no. 4 Suppl 1, ISSN 1934-7820, pages S2 - S7, XP002780488-
OPPOSITION- Tabernero Josep, Et Al, "Encorafenib Plus Cetuximab as a N ew Standard of Care for Previously Treated BRAF VGOOE1\llutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study", Journal of Clinical Oncology, (20210101), vol. 39, no. 4, pages 273 - 285, XP093093529-
OPPOSITION- Wu Pui-Kei, Jong-In Park, "MEKl/2 Inhibitors: Molecular Activity and Resistance Mechanisms", Seminars in Oncology, (20150101), pages 1 - 53, XP093097531-
OPPOSITION- Tabernero J, R. Van Geel, J.C. Bendell, A. Spreafico, M. Schuler, T. Yoshino, J.P. Delord, Y. Yamada, M.P. Lolkema, J.E. Faris, F.A.L.M. Eskens, S. Sharma, R. Yaeger, H.J. Lenz, Z. Wainberg, E. Avsar, A. Chatterjee, S. Jaeger, T. Demuth, J.H.M. Schellens, "11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer", European Journal of Cancer, (20141101), vol. 50, no. Supplement 6, doi:10.1016/S0959-8049(14)70732-4, pages 199 - 199, XP093097512
OPPOSITION- Ascierto Paolo A, Dirk Schadendorf, Carola Berking, Sanjiv S Agarwala, Carla M L Van Herpen, Paola Queirolo, Christian U Blank, Axel Hauschild, J Thaddeus Beck, Annie St-Pierre, Faiz Niazi, Simon Wandel, Malte Peters, Angela Zubel, Reinhard Dummer, "MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study", The Lancet Oncology, (20170301), vol. 14, no. 3, doi:10.1016/S1470-2045(13)70024-X, pages 249 - 256, XP093097537
OPPOSITION- Johanna C Bendell, Milind Javle, Tanios S Bekaii-Saab, Richard S Finn, Zev A Wainberg, Daniel A Laheru, Colin D Weekes, Benjamin R Tan, Gazala N Khan, Mark M Zalupski, Jeffrey R Infante, Suzanne Jones, Kyriakos P Papadopoulos, Anthony W Tolcher, Renae E Chavira, Janna L Christy-Bittel, Emma Barrett, Amita Patnaik, "A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor", British Journal of Cancer, Nature Publishing Group UK, London, London, (20170201), vol. 116, no. 5, doi:10.1038/bjc.2017.10, ISSN 0007-0920, pages 575 - 583, XP055740175
OPPOSITION- Van Cutsem E., Cervantes A., Nordlinger B., Arnold D., "Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Annals of Oncology, (20140901), vol. 25, doi:10.1093/annonc/mdu260, ISSN 0923-7534, pages iii1 - iii9, XP093093527
OPPOSITION- Bendell Johanna C, Kyriakos Papadopoulos; Suzanne F. Jones; Emma Barrett; Kari Guthrie; Carrie L. Kass; Kevin S. Litwiler; Cheryl Napier; Amita Patnaik , "Abstract B243: A phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors", Molecular Cancer Therapeutics, (20111101), vol. 10, no. 11_Supplement, doi:10.1158/1535-7163.TARG-11-B243, pages 1 - 2, XP093097527
OPPOSITION- Akintunde Akinleye;Muhammad Furqan;Nikhil Mukhi;Pavan Ravella;Delong Liu, "MEK and the inhibitors: from bench to bedside", Journal of Hematology & Oncology, BioMed Central Ltd, London UK, London UK , (20130412), vol. 6, no. 27, doi:10.1186/1756-8722-6-27, ISSN 1756-8722, pages 1 - 11, XP021147527
OPPOSITION- Tabernero Robi, Et Al, "Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAFmutant colorectal cancer (BRAFm CRC).", Journal of ClinicalOncology, doi:10.1200/JC0.2016.34.15_suppl.3544, (20160520), pages 1 - 2, Journal of ClinicalOncology, (20231020), XP093093487
OPPOSITION- Kefford Richard, Et Al, "Preliminary results from a phase lb/II, openlabel, dose-escalation study ofthe oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAFV600- dependent advanced solid tumors. ", Journal of Clinical Oncology®, doi:10.1200/jco.2013.31.1, (20130520), pages 1 - 2, Journal of Clinical Oncology®, (20231020), XP093093483
OPPOSITION- Geel Robin Van, Elez Elena, Bendell Johanna C., Faris Jason Edward, Lolkema Martijn P. J. K., Eskens Ferry, Spreafico Anna, Kavan Petr, Delord Jean-Pierre, Schuler Martin H., Wainberg Zev A., Yamada Yasuhide, Yoshino Takayuki, Demuth Tim, Avsar Emin, Chatterjee Arkendu, Zhu Peijuan, Bernards Rene, Tabernero Josep, Schellens Jan Hm, "Phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF -mutant colorectal cancer.", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20140520), vol. 32, no. 15_suppl, doi:10.1200/jco.2014.32.15_suppl.3514, ISSN 0732-183X, pages 3514 - 3514, XP093093485
OPPOSITION- Ryan B Corcoran, "New therapeutic strategies for BRAF mutant colorectal cancers", J Gastrointest Oncol, (20150101), vol. 6, no. 6, doi:10.3978/j.issn.2078-6891.2015.076, pages 650 - 659, XP055314726
SEARCH- Anonymous, "Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)", (20130726), URL: https://www.clinicaltrials.gov/ct2/show/record/NCT01909453, (20191211), XP055651982 [Y] 1-23 * the whole document *-
SEARCH- Reinhard Dummer, "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial", oncology Articles Lancet Oncol Published Online March, (20180101), pages 603 - 15, URL: https://www.sciencedirect.com/science/article/pii/S1470204518301426/pdfft?md5=17bbd2835eae689d8f0f7675f3868e53&pid=1-s2.0-S1470204518301426-main.pdf, (20191211), XP055651822 [YP] 1-23 * the whole document *-
SEARCH- E VAN CUTSEM ET AL, "Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)", ANNALS OF ONCOLOGY, (20150101), vol. 26, doi:10.1093/annonc/mdv262.7, XP055446193 [Y] 1-23 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents